RECURSION PHARMACEUTICALS INC. - CLASS A COMMON S

Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City

19 2 2025 09:00:00 提供 Nasdaq GlobeNewswire

Altitude Lab Startups Raise $154M in Capital

18 2 2025 11:00:00 提供 Nasdaq GlobeNewswire

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

05 2 2025 17:24:48 提供 Nasdaq GlobeNewswire

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

07 1 2025 09:15:00 提供 Nasdaq GlobeNewswire

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

06 1 2025 08:30:00 提供 Nasdaq GlobeNewswire

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

20 12 2024 16:05:00 提供 Nasdaq GlobeNewswire

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

09 12 2024 18:00:00 提供 Nasdaq GlobeNewswire

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

03 12 2024 08:30:00 提供 Nasdaq GlobeNewswire

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

20 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Recursion and Exscientia Shareholders Approve the Proposed Combination

13 11 2024 09:08:19 提供 Nasdaq GlobeNewswire

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

12 11 2024 16:54:03 提供 Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

06 11 2024 16:15:00 提供 Nasdaq GlobeNewswire

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

30 10 2024 08:22:19 提供 Nasdaq GlobeNewswire

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

22 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

02 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

03 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

08 8 2024 14:41:34 提供 Nasdaq GlobeNewswire

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

08 8 2024 07:39:25 提供 Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

08 8 2024 07:30:30 提供 Nasdaq GlobeNewswire

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

08 8 2024 01:32:39 提供 Nasdaq GlobeNewswire